162 related articles for article (PubMed ID: 30516666)
1. A Mixed Variant of Castleman Disease Detected by Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC and 18F-FDG PET/CT.
Pan Q; Zhang X; Luo Y; Ma Y; Li F
Clin Nucl Med; 2019 Feb; 44(2):164-166. PubMed ID: 30516666
[TBL] [Abstract][Full Text] [Related]
2. Unicentric Castleman's Disease Revealed by 18F-FDG PET/CT and Somatostatin Receptor Scintigraphy With 99mTc-HYNIC-TOC.
Luo Y; Wang L; Pan Q; Ma Y; Li F
Clin Nucl Med; 2018 Jul; 43(7):551-552. PubMed ID: 29742598
[TBL] [Abstract][Full Text] [Related]
3. Adrenal Castleman Disease on 99mTc-HYNIC-TOC Scan and FDG PET/CT.
Ding J; Cheng X; Hou G; Jing H; Huo L
Clin Nucl Med; 2021 Jan; 46(1):71-73. PubMed ID: 32956111
[TBL] [Abstract][Full Text] [Related]
4. Hypermetabolic Unicentric Castleman Disease of Kidney on FDG PET/CT.
Wang P; Hou G; Li F; Cheng X
Clin Nucl Med; 2021 Jun; 46(6):510-511. PubMed ID: 33939651
[TBL] [Abstract][Full Text] [Related]
5. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic Pemphigus Associated With Castleman Disease Detected by 18F-FDG PET/CT.
Fu Z; Liu M; Chen X; Yang X; Li Q
Clin Nucl Med; 2018 Jun; 43(6):464-465. PubMed ID: 29561527
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers.
Sager S; Kabasakal L; Halac M; Maecke H; Uslu L; Önsel Ç; Kanmaz B
Clin Nucl Med; 2013 May; 38(5):321-5. PubMed ID: 23531772
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
10. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
[TBL] [Abstract][Full Text] [Related]
11. Colonic Castleman Disease on FDG PET/CT.
Li F; Xiao L; Cai H; Li L
Clin Nucl Med; 2023 Jan; 48(1):71-72. PubMed ID: 35961369
[TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT Findings in TAFRO Syndrome.
Hotta M; Minamimoto R; Yashima A; Nakano M; Yamashita H
Clin Nucl Med; 2018 Nov; 43(11):828-829. PubMed ID: 30222681
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTATATE and 18F-FDG in Castleman Disease.
Verçosa AFA; Flamini MEDM; Loureiro LVM; Flamini RC
Clin Nucl Med; 2020 Nov; 45(11):868-870. PubMed ID: 32969902
[TBL] [Abstract][Full Text] [Related]
14. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
16. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
[TBL] [Abstract][Full Text] [Related]
17.
He L; Chen Y; Tan X; Sun X; Zhang Q; Luo H; Jiang L
Jpn J Radiol; 2023 Jan; 41(1):98-107. PubMed ID: 35895223
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
[TBL] [Abstract][Full Text] [Related]
19. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
20. PET/CT imaging with 18F-FDG in Castleman disease.
Delgado A; Mesa J; Guayambuco S; Rodriguez T; Fernández I; Rodeño E
Rev Esp Med Nucl Imagen Mol; 2016; 35(3):200-1. PubMed ID: 26614744
[No Abstract] [Full Text] [Related]
[Next] [New Search]
